- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07696364
Evaluation of the Anti-septic Effect of a Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) During Experimental Gingivitis
Protocol Title Evaluation of the Anti-septic Effect of a Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) Compared to Placebo, During Experimental Gingivitis
Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.
Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation.
During the study period, participants will be asked to rinse with the mouthrinse sample or the placebo for 60 seconds twice daily, under video supervision (participants send in video recordings of their rinsing to control adherence to the protocol). A dental assistant, unaware of the study's purpose, will distribute the samples. The containers will be unlabeled, ensuring that both the participants and examiners are blinded to group allocation.
At Days 0, 7, 14 and 21 of the experiment, clinical examinations will be performed from central incisors to the second molars in each participant. The Discoloration Index (DI17) will be recorded at three aspects on each tooth (mesial, buccal and distal). The criteria for the Discoloration Index (DI) are indicated in Table 1. Plaque and Gingivitis Indices will be assessed at 4 aspects of each tooth (mesial, buccal, distal and lingual) using the criteria of the Plaque Index system (PlI) (Silness & Löe 1964) and the Gingival Index System (GI) (Löe & Silness 1963) 16, 18. At each visit, the parameters will be assessed by the same examiner, who will be masked by the allocation of the test and control to avoid examiner bias and calibration bias.
Upon completion of the experimental period, mechanical daily plaque control measures will be re-instated and the participants will be re-examined after 3 weeks to ensure their periodontal health. Following the experimental period, another professional cleansing will be performed to remove plaque and possible stain on the teeth. At day 35 the participants will be checked again.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Canton of Bern
-
Bern, Canton of Bern, Švýcarsko, 3010
- Department of Periodontology, University of Bern
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- systemically healthy,
- non-smoker, former smokers > 5 years,
- at least 24 teeth,
- clinical diagnosis of periodontal health or gingivitis as determined by pocket probing depth not exceeding 4 mm with concomitant bleeding on probing.
Exclusion Criteria:
- clinically visible carious lesions,
- systemic antibiotics within 3 months prior to enrolment
- vulnerable persons
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Komparátor placeba: Placebo Group
Group P rinses twice daily with 10 ml of a placebo (pure water with flavored additive) solution
|
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero.
The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
|
|
Experimentální: Group T1
Group T1 rinses twice daily with 10 ml of 0.12% chlorhexidine solution with ADS (Anti-Discoloration System) solution (Curasept ADS 212)
|
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero.
The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
|
|
Experimentální: Group T2
Group T2 rinses twice daily with 10 ml of 0.12% chlorhexidine with HA (Hyaluronic Acid)
|
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero.
The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
Časové okno: at day 21
|
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
|
at day 21
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
Časové okno: at day 0, 7, 14, and 35
|
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
|
at day 0, 7, 14, and 35
|
|
Plaque accumulation, assessed by the Plaque Index Silness and Löe 1994
Časové okno: at day 0, 7, 14, 21 and 35
|
The index is a scoring system assessing the plaque at 4 surfaces of the teeth, starting at 0 for no plaque visible to 3 with an abundance of plaque creating a thick layer that fills the interdental space.
|
at day 0, 7, 14, 21 and 35
|
|
Staining assessed by the Discoloration index
Časové okno: at day 0, 7, 14, 21 and 35
|
The discoloration is an index from 0: no discoloration to 3: Heavy brown and black discoloration over the entire extent of the tooth surface, black discoloration predominantly on the interproximal surfaces
|
at day 0, 7, 14, 21 and 35
|
|
Oral scan
Časové okno: at day 0, 21 and 35
|
Oral scans will be performed to study changes in gingival texture, volume and colour or other changes
|
at day 0, 21 and 35
|
|
Microbiological changes
Časové okno: at day 0, 21 and 35
|
Changes in 8 periodontopathogens will be assessed by Multiplex PCR
|
at day 0, 21 and 35
|
|
Characterisation of host- and microbiome-derived metabolites
Časové okno: at day 0, 21 and 35
|
From selective participants, host-derived metabolites will be assessed by untargeted liquid chromatography-mass spectrometry (LC-MS) to study molecular changes throughout disease progression and possible relationships with other generated datasets.
|
at day 0, 21 and 35
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- V4ExpAugGingivitis
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Gingivitis Infection
-
Jianfeng XieNáborCLABSI - Central Line Associated Bloodstream InfectionČína
-
Mahidol UniversityDokončenoCLABSI - Central Line Associated Bloodstream InfectionThajsko
-
Assiut UniversityZatím nenabírámeCLABSI - Central Line Associated Bloodstream Infection | Periferně zavedený centrální katétr | Pupeční žilní katétr
-
Schülke & Mayr GmbHDokončenoInhibice tvorby plaku (podle Gingivitis-Index ≤1,5)Německo
-
Schülke & Mayr GmbHDokončenoInhibice tvorby plaku (podle Gingivitis-Index ≤1,5)Rakousko, Německo
-
Helsinki University Central HospitalUniversity of Turku; Oulu University Hospital; Kuopio University Hospital; Tampere... a další spolupracovníciNáborHysterektomie | Antibiotika | Infection Post Op | ProfylaktickýFinsko
-
Fundacion Clinic per a la Recerca BiomédicaDokončenoProtheses infectionŠpanělsko
-
Sinocelltech Ltd.NáborHPV Infection Vaccine Safety SCT1000Čína
-
Duke UniversityDokončenoCentral Line-associated Bloodstream Infection (CLABSI)Spojené státy
-
Catholic University of the Sacred HeartDokončenoCentral Line-associated Bloodstream Infection (CLABSI)
Klinické studie na Experimental gingivitis model
-
Cardenal Herrera UniversityDokončenoHypertenze | ObezitaŠpanělsko
-
University of BurgundyDokončeno
-
Reistone Biopharma Company LimitedDokončeno
-
Taisy Cinthia Ferro CavalcanteNáborKardiovaskulární choroby | Polyfenoly | Autonomní nervový systémBrazílie
-
The Hospital for Sick ChildrenDokončeno
-
PfizerDokončeno
-
PfizerDokončeno